Mainstream Perp DEX Overview: Hyperliquid's Open Interest Surges Over $8 Billion, Aster Leads in Trading Volume
BlockBeats News, January 5th, according to DefiLlama data, in the past 24 hours, the overall trading volume of Perp DEX saw a slight rebound, with Aster ranking first with a trading volume of 38 billion U.S. dollars. At the same time, the open interest of the Hyperliquid platform continues to grow, rising by about 15% compared to last week, hitting a new nearly 30-day high, indicating increased short-term risk. The current partial Perp DEX trading volumes are as follows:
Aster 24-hour trading volume approximately 38.8 billion U.S. dollars, TVL approximately 12.5 billion U.S. dollars, open interest 26.3 billion U.S. dollars;
Hyperliquid 24-hour trading volume approximately 34.8 billion U.S. dollars, TVL approximately 42.3 billion U.S. dollars, open interest 81.7 billion U.S. dollars;
Lighter 24-hour trading volume approximately 33.9 billion U.S. dollars, TVL approximately 12.6 billion U.S. dollars, open interest 14 billion U.S. dollars;
EdgeX 24-hour trading volume approximately 28.3 billion U.S. dollars, TVL approximately 3.58 billion U.S. dollars, open interest 8.88 billion U.S. dollars;
Paradex 24-hour trading volume approximately 17.8 billion U.S. dollars, TVL approximately 1.72 billion U.S. dollars, open interest 8.16 billion U.S. dollars;
Variational 24-hour trading volume approximately 16.1 billion U.S. dollars, TVL approximately 66.18 million U.S. dollars, open interest 8.4 billion U.S. dollars;
Pacifica 24-hour trading volume approximately 6.77 billion U.S. dollars, TVL approximately 43.11 million U.S. dollars, open interest 77.34 million U.S. dollars.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The S&P 500 Index closed down 64.99 points, a decrease of 0.94%, at 6816.63 points.
Trending news
MoreAccording to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.
Moderna, Inc. (MRNA) has recently updated its financial outlook, announcing an adjustment of its expected cash and cash equivalents at the end of 2026 to a range of $4.5 billion to $5.0 billion.
